Table 2 Response rates in patients who underwent surgery

From: Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study

Efficacy outcomes

Arm A (n = 15)

Arm B (n = 9)

Pathological response, n (%, 95% CI)

 Major pathological response

3 (20.0, 4.3–48.1)

5 (55.6, 21.2–86.3)

 Pathological complete response

3 (20.0, 4.3–48.1)

1 (11.1, 0.3–48.2)

Best overall response, n (%)

 Complete response

0

0

 Partial response

5 (33.3)

5 (55.6)

 Stable disease

8 (53.3)

4 (44.4)

 Not evaluable

2 (13.3)

0

Objective response rate, % (95% CI)

33.3 (11.8–61.6)

55.6 (21.2–86.3)